Search

Your search keyword '"van Biezen, Anja"' showing total 16 results
Start Over Author "van Biezen, Anja" Journal bone marrow transplantation
16 results on '"van Biezen, Anja"'

1. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison

Author

Beelen, Dietrich Wilhelm, primary, Iacobelli, Simona, additional, Koster, Linda, additional, Eikema, Dirk-Jan, additional, van Biezen, Anja, additional, Stölzel, Friedrich, additional, Ciceri, Fabio, additional, Bethge, Wolfgang, additional, Dreger, Peter, additional, Wagner-Drouet, Eva-Maria, additional, Reményi, Péter, additional, Stelljes, Matthias, additional, Markiewicz, Miroslaw, additional, McLornan, Donal P., additional, Yakoub-Agha, Ibrahim, additional, and Mohty, Mohamad, additional

Published
2024
Full Text
View/download PDF

2. Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT

Author

Styczynski, Jan, primary, Tridello, Gloria, additional, Koster, Linda, additional, Knelange, Nina, additional, Wendel, Lotus, additional, van Biezen, Anja, additional, van der Werf, Steffie, additional, Mikulska, Malgorzata, additional, Gil, Lidia, additional, Cordonnier, Catherine, additional, Ljungman, Per, additional, Averbuch, Diana, additional, Cesaro, Simone, additional, Baldomero, Helen, additional, Chabannon, Christian, additional, Corbacioglu, Selim, additional, Dolstra, Harry, additional, Glass, Bertram, additional, Greco, Raffaella, additional, Kröger, Nicolaus, additional, de Latour, Régis Peffault, additional, Mohty, Mohamad, additional, Neven, Benedicte, additional, Peric, Zinaida, additional, Snowden, John A., additional, Sureda, Anna, additional, Yakoub-Agha, Ibrahim, additional, and de la Camara, Rafael, additional

Published
2023
Full Text
View/download PDF

3. Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study

Author

Schetelig, Johannes, primary, Hoek, Jennifer, additional, Stilgenbauer, Stephan, additional, Middeke, Jan Moritz, additional, Andersen, Niels Smedegaard, additional, Fox, Christopher P., additional, Lenhoff, Stig, additional, Volin, Liisa, additional, Shimoni, Avichai, additional, Schroyens, Wilfried, additional, van Gelder, Michel, additional, Bunjes, Donald, additional, van Biezen, Anja, additional, Baldauf, Henning, additional, de Wreede, Liesbeth C., additional, Tournilhac, Olivier, additional, Kröger, Nicolaus, additional, Yakoub-Agha, Ibrahim, additional, and Dreger, Peter, additional

Published
2021
Full Text
View/download PDF

4. Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT

Author

Ruggeri, Loredana, primary, Vago, Luca, additional, Eikema, Diderik-Jan, additional, de Wreede, Liesbeth C., additional, Ciceri, Fabio, additional, Diaz, Miguel Angel, additional, Locatelli, Franco, additional, Jindra, Pavel, additional, Milone, Giuseppe, additional, Diez-Martin, Josè Luis, additional, Pérez-Simón, Jose Antonio, additional, Merluzzi, Mara, additional, Koster, Linda, additional, van der Werf, Steffie, additional, van Biezen, Anja, additional, Toubert, Antoine, additional, Nagler, Arnon, additional, Chabannon, Christian, additional, Bonini, Chiara, additional, and Velardi, Andrea, additional

Published
2021
Full Text
View/download PDF

5. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Author

Schetelig, Johannes, primary, Hoek, Jennifer, additional, Stilgenbauer, Stephan, additional, Middeke, Jan Moritz, additional, Andersen, Niels Smedegaard, additional, Fox, Christopher P., additional, Lenhoff, Stig, additional, Volin, Liisa, additional, Shimoni, Avichai, additional, Schroyens, Wilfried, additional, van Gelder, Michel, additional, Bunjes, Donald, additional, van Biezen, Anja, additional, Baldauf, Henning, additional, de Wreede, Liesbeth C., additional, Tournilhac, Olivier, additional, Kröger, Nicolaus, additional, Yakoub-Agha, Ibrahim, additional, and Dreger, Peter, additional

Published
2020
Full Text
View/download PDF

6. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Author

Morris, Curly, primary, Chabannon, Christian, additional, Masszi, Tamas, additional, Russell, Nigel, additional, Nahi, Hareth, additional, Kobbe, Guido, additional, Krejci, Marta, additional, Auner, Holger W., additional, Pohlreich, David, additional, Hayden, Patrick, additional, Basak, Grzegorz W., additional, Lenhoff, Stig, additional, Schaap, Nicolaas, additional, van Biezen, Anja, additional, Knol, Cora, additional, Iacobelli, Simona, additional, Liu, Qianying, additional, Celanovic, Marina, additional, Garderet, Laurent, additional, and Kröger, Nicolaus, additional

Published
2019
Full Text
View/download PDF

7. Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT

Author

Ruutu, Tapani, primary, van der Werf, Steffie, additional, van Biezen, Anja, additional, Backman, Janne T., additional, Peczynski, Christophe, additional, Kröger, Nicolaus, additional, Mohty, Mohamad, additional, Nagler, Arnon, additional, Montoto, Silvia, additional, Langebrake, Claudia, additional, Niederwieser, Dietger, additional, Peric, Zinaida, additional, Koenecke, Christian, additional, Duarte, Rafael F., additional, and Basak, Grzegorz, additional

Published
2019
Full Text
View/download PDF

8. Variability of nutritional practices in peritransplant period after allogeneic hematopoietic stem cell transplantation: a survey by the Complications and Quality of Life Working Party of the EBMT

Author

Peric, Zinaida, primary, Botti, Stefano, additional, Stringer, Jacqui, additional, Krawczyk, Joanna, additional, van der Werf, Steffie, additional, van Biezen, Anja, additional, Aljurf, Mahmoud, additional, Murray, John, additional, Liptrott, Sarah, additional, Greenfield, Diana M., additional, Duarte, Rafael F., additional, Ruutu, Tapani, additional, and Basak, Grzegorz W., additional

Published
2018
Full Text
View/download PDF

9. Allogeneic hematopoietic cell transplantation for patients with TP53mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Author

Schetelig, Johannes, Hoek, Jennifer, Stilgenbauer, Stephan, Middeke, Jan Moritz, Andersen, Niels Smedegaard, Fox, Christopher P., Lenhoff, Stig, Volin, Liisa, Shimoni, Avichai, Schroyens, Wilfried, van Gelder, Michel, Bunjes, Donald, van Biezen, Anja, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Kröger, Nicolaus, Yakoub-Agha, Ibrahim, and Dreger, Peter

Published
2021
Full Text
View/download PDF

10. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Author

Morris, Curly, Chabannon, Christian, Masszi, Tamas, Russell, Nigel, Nahi, Hareth, Kobbe, Guido, Krejci, Marta, Auner, Holger W., Pohlreich, David, Hayden, Patrick, Basak, Grzegorz W., Lenhoff, Stig, Schaap, Nicolaas, van Biezen, Anja, Knol, Cora, Iacobelli, Simona, Liu, Qianying, Celanovic, Marina, Garderet, Laurent, and Kröger, Nicolaus

Abstract

Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.

Published
2020
Full Text
View/download PDF

11. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors

Author

Styczyński, Jan, Tridello, Gloria, Koster, Linda, Iacobelli, Simona, van Biezen, Anja, van der Werf, Steffie, Mikulska, Małgorzata, Gil, Lidia, Cordonnier, Catherine, Ljungman, Per, Averbuch, Diana, Cesaro, Simone, de la Camara, Rafael, Baldomero, Helen, Bader, Peter, Basak, Grzegorz, Bonini, Chiara, Duarte, Rafael, Dufour, Carlo, Kuball, Jurgen, Lankester, Arjan, Montoto, Silvia, Nagler, Arnon, Snowden, John A., Kröger, Nicolaus, Mohty, Mohamad, and Gratwohl, Alois

Abstract

Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55′668 deaths in 114′491 patients with HSCT (83.7% allogeneic) for leukemia were investigated in a landmark analysis for causes of death at day 30 (very early), day 100 (early), at 1 year (intermediate) and at 5 years (late). Mortality from all causes decreased from cohort 1 (1980–2001) to cohort 2 (2002–2015) in all post-transplant phases after autologous HSCT. After allogeneic HSCT, mortality from infections, GVHD, and toxicity decreased up to 1 year, increased at 5 years; deaths from relapse increased in all post-transplant phases. Infections of unknown origin were the main cause of infectious deaths. Lethal bacterial and fungal infections decreased from cohort 1 to cohort 2, not unknown or mixed infections. Infectious deaths were associated with patient-, disease-, donor type, stem cell source, center, and country- related factors. Their impact varied over the post-transplant phases. Transplant centres have successfully managed to reduce death after HSCT in the early and intermediate post-transplant phases, and have identified risk factors. Late post-transplant care could be improved by focus on groups at risk and better identification of infections of “unknown origin”.

Published
2020
Full Text
View/download PDF

12. Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting

Author

Bondanza, Attilio, Ruggeri, Loredana, Noviello, Maddalena, Eikema, Dirk-Jan, Bonini, Chiara, Chabannon, Christian, van der Werf, Steffie, van Biezen, Anja, de Wreede, Liesbeth C., Crucitti, Lara, Vago, Luca, Merluzzi, Mara, Massei, Maria Speranza, Veelken, Hendrik, Koc, Yener, Bader, Peter, Gruhn, Bernd, Locatelli, Franco, Ciceri, Fabio, Toubert, Antoine, and Velardi, Andrea

Abstract

HLA-haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is increasingly offered to patients with high-risk acute leukaemia. Unfortunately, haplo-HSCT is followed by a delayed immunoreconstitution. The aim of this EBMT registry study was to explore the clinical impact of lymphocyte subset counts after haplo-HSCT. We considered 144 leukaemic patients transplanted in the period 2001–2012. Pre-transplantation clinical variables and differential immune-cell counts (CD3, CD4, CD8 T cells, NK and B cells) measured before day 100 were evaluated for their capacity to predict overall survival, relapse mortality or non-relapse mortality (NRM). Negative prognostic factors for overall survival were advanced disease state at transplantation, host age and CMV seropositivity. Higher CD3, CD4 and CD8 counts were associated with a better overall survival and a lower NRM. Strikingly, when tested in multivariable analysis, higher CD3 and CD8 counts were still significantly associated with a lower NRM. These results indicate that an accelerated T-cell reconstitution correlates with less transplantation mortality, likely due to the protective role of T cells against viral infections. This observation suggests that CD8+ T-cell counts should be investigated as surrogate biomarkers of outcome in prospective haplo-HSCT trials.

Published
2019
Full Text
View/download PDF

13. Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study

Author

Schetelig, Johannes, Hoek, Jennifer, Stilgenbauer, Stephan, Middeke, Jan Moritz, Andersen, Niels Smedegaard, Fox, Christopher P., Lenhoff, Stig, Volin, Liisa, Shimoni, Avichai, Schroyens, Wilfried, van Gelder, Michel, Bunjes, Donald, van Biezen, Anja, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Kröger, Nicolaus, Yakoub-Agha, Ibrahim, and Dreger, Peter

Published
2022
Full Text
View/download PDF

14. Beneficial role of CD8+T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias

Author

Bondanza, A., Ruggeri, L., Noviello, M., Eikema, D.J., Bonini, C., Chabannon, C., Werf, S. van der, Biezen, A. van, Wreede, L.C. de, Crucitti, L., Vago, L., Merluzzi, M., Massei, M.S., Veelken, H., Koc, Y., Bader, P., Gruhn, B., Locatelli, F., Ciceri, F., Toubert, A., Velardi, A., Bernardo, M.E., Dazzi, F., Ellard, R., Fleischhauer, K., Greco, R., Hudecek, M., Kohl, U., Kuball, J., Malard, F., Pedrazzoli, P., Rocha, V., Ruggeri, A., Urbano-Ispizua, A., Wang, J.F., Wieten, L., EBMT Cell Therapy Immunobiol Worki, Bondanza, Attilio, Ruggeri, Loredana, Noviello, Maddalena, Eikema, Dirk-Jan, Bonini, Chiara, Chabannon, Christian, van der Werf, Steffie, van Biezen, Anja, de Wreede, Liesbeth C., Crucitti, Lara, Vago, Luca, Merluzzi, Mara, Massei, Maria Speranza, Veelken, Hendrik, Koc, Yener, Bader, Peter, Gruhn, Bernd, Locatelli, Franco, Ciceri, Fabio, Toubert, Antoine, Velardi, Andrea, MUMC+: DA TI Laboratorium (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: DA TI Staf (9)

Subjects
Male, Oncology, BLOOD, COUNT, Medizin, CHILDREN, CD8-Positive T-Lymphocytes, DISEASE, 0302 clinical medicine, Risk Factors, hemic and lymphatic diseases, Cytotoxic T cell, Registries, Child, INDEX, Leukemia, Hematology, Middle Aged, RECOVERY, Haematopoiesis, surgical procedures, operative, medicine.anatomical_structure, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Transplantation, Child, Preschool, 030220 oncology & carcinogenesis, HSCT, Female, Stem cell, Adult, medicine.medical_specialty, Adolescent, T cell, Human leukocyte antigen, Young Adult, 03 medical and health sciences, CD8-positive T-lymphocytes, haematopoietic stem cell transplantation, risk factors, Internal medicine, SCORE, medicine, Humans, IMMUNOTHERAPY, Aged, business.industry, ADULTS, BONE-MARROW-TRANSPLANTATION, Transplantation, Haploidentical, business, CD8, Stem Cell Transplantation, 030215 immunology, RESPONSES
Abstract

HLA-haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is increasingly offered to patients with high-risk acute leukaemia. Unfortunately, haplo-HSCT is followed by a delayed immunoreconstitution. The aim of this EBMT registry study was to explore the clinical impact of lymphocyte subset counts after haplo-HSCT. We considered 144 leukaemic patients transplanted in the period 2001-2012. Pre-transplantation clinical variables and differential immune-cell counts (CD3, CD4, CD8 T cells, NK and B cells) measured before day 100 were evaluated for their capacity to predict overall survival, relapse mortality or non-relapse mortality (NRM). Negative prognostic factors for overall survival were advanced disease state at transplantation, host age and CMV seropositivity. Higher CD3, CD4 and CD8 counts were associated with a better overall survival and a lower NRM. Strikingly, when tested in multivariable analysis, higher CD3 and CD8 counts were still significantly associated with a lower NRM. These results indicate that an accelerated T-cell reconstitution correlates with less transplantation mortality, likely due to the protective role of T cells against viral infections. This observation suggests that CD8+ T-cell counts should be investigated as surrogate biomarkers of outcome in prospective haplo-HSCT trials.

Published
2019

16. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study.

Author

Schetelig J, Hoek J, Stilgenbauer S, Middeke JM, Andersen NS, Fox CP, Lenhoff S, Volin L, Shimoni A, Schroyens W, van Gelder M, Bunjes D, van Biezen A, Baldauf H, de Wreede LC, Tournilhac O, Kröger N, Yakoub-Agha I, and Dreger P

Subjects
Humans, Prospective Studies, Transplantation, Homologous, Tumor Suppressor Protein p53 genetics, Hematopoietic Stem Cell Transplantation, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell therapy
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results